14652
document
[ Mitoxantrone ( MTX ) versus mitomycin C ( MMC ) in the ablative treatment of Ta , T1 superficial bladder tumors . Phase III , randomized prospective study ] . A prospective randomized study was conducted to determine the ablation capacity of mitoxantrone in Ta-T1 superficial bladder tumors versus mitomycin C , a drug whose intravesical ablation properties are well-known . Fifty-seven patients comprised the study . The tumor was not completely resected when the patient underwent TUR . This residual tumor was used as control . The patients were treated with either 20 mg Mitoxantrone or 40 mg mitomycin C weekly for 8 weeks and two other instillations every 15 days in 50 ml saline solution . Response to therapy was evaluated between the 4th and 8th week and classified as complete response ( CR ) , defined as no gross and microscopic evidence of residual tumor , or no response ( NR ) or therapeutic failure . CR was observed in 77.7 % of the patients treated with mitomycin C and in 50 % in those that had been treated with Mitoxantrone . Treatment was discontinued because of side effects in 15 % of the patients treated with mitomycin C and in 63.4 % of those who received Mitoxantrone . We can conclude from the results of the present study that Mitoxantrone is a useful agent for ablation therapy of superficial bladder tumors , although the high incidence of severe side effects warrants its limited use and at high dilutions .
14653
Intervention_Pharmacological
[ Mitoxantrone ( MTX ) versus mitomycin C ( MMC )
14654
Intervention_Pharmacological
mitoxantrone
14655
Intervention_Pharmacological
mitomycin C
14656
Intervention_Pharmacological
Mitoxantrone
14657
Intervention_Pharmacological
mitomycin C
14658
Intervention_Pharmacological
mitomycin C
14659
Intervention_Pharmacological
Mitoxantrone
14660
Intervention_Pharmacological
mitomycin C
14661
Intervention_Pharmacological
Mitoxantrone
14662
Intervention_Pharmacological
Mitoxantrone
14663
Outcome_Physical
ablation capacity
14664
Outcome_Other
Response to therapy
14665
Outcome_Other
complete response ( CR )
14666
Outcome_Physical
gross and microscopic evidence of residual tumor
14667
Outcome_Other
no response ( NR )
14668
Outcome_Other
therapeutic failure
14669
Outcome_Adverse-effects
side effects
14670
Outcome_Adverse-effects
side effects
14671
Participant_Condition
Ta , T1 superficial bladder tumors
14672
Participant_Sample-size
Fifty-seven